Date: 2014-07-24
Type of information: Grant
Company: University of Birmingham (UK) Biotie Therapies (Finland)
Investors: National Institute for Health Research (NIHR) (UK)
Amount: € 1 million
Funding type: grant
Planned used: The award will support an investigator-sponsored, Phase 2, proof of concept study with Biotie\'s vascular adhesion protein-1 (VAP-1) antibody, BTT1023, in primary sclerosing cholangitis (PSC). PSC is a chronic and progressive orphan fibrotic disease for which there are currently no approved therapeutic treatments. The study will be conducted in the UK and is expected to start recruiting patients by the end of 2014. The investigator-sponsored study will be an open label, single arm, multi-centre study enrolling 41 patients which will examine the efficacy, safety and pharmacokinetic properties of BTT1023 in patients with primary sclerosing choloangitis. The duration of drug treatment in the study is 11 weeks and the primary efficacy endpoint will be reduction of elevated levels of alkaline phosphatase, a blood biomarker of bile duct inflammation.
Others: * On July 24, 2014, Biotie Therapies announced that the clinical study with BTT1023 in primary sclerosing cholangitis awarded external grant funding. Biotie Therapies Corp. will be working in partnership with the University of Birmingham, UK, who have been awarded funding of up to approximately € 1.0 million for an investigator-sponsored, Phase 2, proof of concept study with BTT1023, in primary sclerosing cholangitis (PSC). The grant holder and Chief Investigator for the study is Professor David Adams Director of the National Institute for Health Research (NIHR) Biomedical Research Unit in Liver Disease and Centre for Liver Research at the University of Birmingham. This project was awarded by the NIHR Efficacy and Mechanism Evaluation (EME) Programme* and is funded and managed by the National Institute for Health Research (NIHR) on behalf of the MRC-NIHR partnership. Biotie retains full rights to BTT1023.
Therapeutic area: Inflammatory diseases
